Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma

Journal of Immunology

Volumn 176, Issue 6, 2006, Pages 3461-3469

  Iinuma, Hisae ^a   Okinaga, Kota ^a   Fukushima, Ryoji ^a   Inaba, Tsuyoshi ^a   Iwasaki, Kota ^a   Okinaga, Akira ^a   Takahashi, Ichiro ^a   Kaneko, Michio ^b  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; MACROGOL; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ELECTROPORATION; FEMALE; FUSION GENE; GENETIC TRANSDUCTION; IL 12 GENE; IL 18 GENE; IMMUNE RESPONSE; INTERFERON PRODUCTION; LACZ GENE; LIVER METASTASIS; MOUSE; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

EID: 33644843971     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.6.3461     Document Type: Article

References (44)

1. Isaacs, H., Jr. 1997. Neuroblastoma. In Tumors of the fetus and newborn. K. T. Oldham, P. M. Colombani, and R. P. Foglia, eds. Scientific Principles and Practice, Lippincott-Raven, Philadelphia, pp. 130-149.
2. Young, J. L., L. G. Ries, E. Silverberg, J. W. Horm, and R. W. Miller. 1986. Cancer incidences, survival and mortality for children younger than age 15 years. Cancer 58: 598-602.
3. Nagabuchi, E., and M. M. Ziegler. 1997. Neuroblastoma. In Surgery of Infants and Children. K. T. Oldham, P. M. Colombani, and R. P. Foglia, eds. Scientific Principles and Practice, Lippincott-Raven, Philadelphia, PA, pp. 593-613.
4. Grosfeld, J. L., F. J. Rescorla, K. W. West, and J. Goldman. 1993. Neuroblastoma in the first year of life: clinical and biological factors influencing outcome. Semin. Pediatr. Surg. 2: 37-46.
5. Cooper, M. J., G. M. Hutchins, R. J. Mennie, and M. A. Israel. 1990. β2-microglobulin expression in human embryonal neuroblastoma reflects its developmental regulation. Cancer Res. 50: 3694-3700.
6. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9: 271-296.
7. Reid, D. C. 2001. Dendritic cells and immunotherapy for malignant disease. Br. J. Haematol. 112: 874-887.
8. Nestle, F. O., S. Aliagic, M. Gilliet, Y. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4: 328-332.
9. Chang, A. E., B. G. Redman, J. R. Whitfield, B. J. Nickoloff, T. M. Braun, P. P. Lee, J. D. Geiger, and J. J. Muller. 2002. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 8: 1021-1032.
10. Matsuda, K., T. Tsunoda, H. Tanaka, Y. Umano, H. Tanimura, I. Nukaya, and K. Takesako. 2004. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol. Immunother. 53: 609-616.
11. Nair, S. K., M. Morse, D. Boczkowski, R. I. Cumming, L. Vasovic, E. Gilboa, and H. K. Lyerly. 2002. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 235: 540-549.
12. Coughlin, C. M., B. A. Vance, S. A. Grupp, and R. H. Vonderheide. 2004. RNA-transfected CD40-acivated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103: 2046-2054.
13. Rodolfo, M., R. Luksch, S. Elisabeth, Y. T. Chen, P. Collini, T. Ranzani, C. Lombardo, P. Dalerba, L. Rivoltini, F. Arienti, et al. 2003. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res. 63: 6948-6955.
14. Sarkar A. K., and J. G. Nuchtern. 2000. Lysis of MYCN-amplified neuroblastoma cells y MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res. 60: 1908-1913.
15. Gong, J., D. Chen, M. Kashiwaba, and D. Kufe. 1997. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3: 558-561.
16. Homma, S., G. Toda, J. Gong, D. Kufe, and T. Ohno. 2001. Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J. Gastroenterol. 36: 764-771.
17. Orentas, R., D. Schauer, Q. Bin, and B. D. Johnson. 2001. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cellular Immunol. 213: 4-13.
18. Wang, J., S. Saffold, X. Cao, J. Krauss, and W. Chen. 1998. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 161: 5516-5524.
19. Gottfried, E., R. Krieg, C. Eichelberg, R. Andreesen, A. Mackensen, and S. W. Krause. 2002. Characterization of cells prepared by dendritic cell-tumor cell fusion. Cancer Immunity 2: 15-36.
20. Kao, J. Y., Y. Gong, C. M. Chen, Q. D. Zheng, and J. J. Chen. 2003. Tumor-derived TGF-β reduces the efficacy of dendritic cell/tumor fusion vaccine. J. Immunol. 170: 3806-3811.
21. Trevor, K. T., C. Cover, Y. W. Ruiz, E. T. Akporiaye, E. M. Hersh, D. Landais, R. R. Taylor, A. D. King, and R. E. Walters. 2004. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunol. Immunother. 53: 705-774.
22. Gubler, U., A. O. Chua, D. S. Schoenhaut, C. M. Dwyer, W. McComas, R. Motyka, N. Nabavi, A. G. Wolitzky, P. M. Quinn, P. C. Familletti, and M. K. Gately. 1991. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. USA 88: 4143-4147.
23. Wolf, S. F., P. A. Temple, M. Kobayashi, D. Young, M. Dicig, L. Lowe, R. Dzialo, L. Fitz, C. Ferenz, R. M. Hewick, et al. 1991. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol. 146: 3074-3081.
24. Kobayashi, M., L. Fitz, M. Ryan, R. Hewick, S. C. Clark, S. Chang, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170: 827-845.
25. Gately, M. K., A. G. Wolitzky, P. N. Quinn, and R. Chizzonite. 1992. Regulation of human cytotoxic lymphocytes response by interleukin-12. Cell Immunol. 143: 127-142.
26. Robertson, M. J., R. J. Soiffer, S. F. Wolf, T. J. Manley, C. Donahue, D. Young, S. H. Herrmann, and J. Ritz. 1992. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. Exp. Med. 175: 779-788.
27. Okamura, H., H. Tsutsi, T. Komatsu, M. Yitsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, et al. 1995. Cloning a new cytokine that induces IFN-γ production by T cells. Nature 378: 88-91.
28. Okamura, H., K. Nagata, T. Komatsu, T. Tanimoto, Y. Nukata, F. Tanabe, K. Akita, K. Torigoe, T. Okura, S. Fukuda, and M. Kurimoto. 1995. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxin shock. Infect. Immun. 63: 3966-3972.
29. Tsutsui, H., K. Matsui, and N. Kawada. 1997. IL-18 accounts for both TNF-α and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J. Immunol. 159: 3961-3973.
30. Fukao T., S. Matsuda, and S. Koyasu. 2000. Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-γ production by dendritic cells. J. Immunol. 164: 64-71.
31. Kishida, T., H. Asada, E. Satoh, S. Tanaka, M. Shinya, H. Hirai, H. Tahara, J. Imanishi, and O. Mazda. 2001. In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther. 8: 1234-1240.
32. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176: 1693-1702.
33. Yoshimura, K., S. Hazama, N. Iizuka, S. Yoshino, K. Yamamoto, M. Muraguchi, Y. Ohmoto, T. Noma, and M. Oka. 2001. Successsful immunogene therapy using colon cancer cells (colon 26) transduced with plasmid vector containing mature interleukin-18 cDNA and the Igκ leader sequence. Cancer Gene Ther. 8: 9-16.
34. Miyake, S., M. Makimura, M. Kanegae, S. Harada, Y. Sato, K. Takamori, C. Tokuda, and I. Saito. 1996. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc. Natl. Acad. Sci. USA 93: 1320-1324.
35. Geiger, J. D., R. J. Hutchinson, L. F. Hohenkirk, E. A. McKenna, G. A. Yanik, J. E. Levine, A. E. Chang, T. M. Braun, and J. J. Mule. 2001. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cell mediate tumor regression. Cancer Res. 61: 8513-8519.
36. Ogawa, F., H. Iinuma, and K. Okinaga. 2004. Dendritic cell vaccine therapy by immunization with fusion cells of IL-2-gene-transduced dendritic cells and tumor cells. Scan. J. Immunol. 59: 432-439.
37. Kikuchi, T., Y. Akasaki, M. Irie, S. Homma, T. Abe, and T. Ohno. 2001. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 50: 337-344.
38. Märten, A., S. Renoth, T. Heinicke, P. Albers, A. Pauli, U. Mey, R. Casparo, D. Flieger, P. Hanfland, A. V. Ruecker, et al. 2003. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 14: 483-494.
39. Trefzer, U., G. Herberth, K. Wohlan, A. Milling, M. Thiemann, T. Sharav, K. Sparbier, W. Sterry, and P. Walden. 2005. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine 23: 2367-2373.
40. Bauer, M., G. H. Reaman, J. A. Hank, M. S. Cairo, P. Anderson, B. R. Blazar, S. Frierdich, and P. M. Condel. 1995. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma: a Childrens Cancer Group study. Cancer 75: 2959-2965.
41. Rueda, F., F. Marti, N. Pardo, I. Badell, M. Peiro, E. Bertran, E. Villen, J. Garcia, and J. Cubells. 1996. Interleukin-2 in neuroblastoma: clinical perspectives based on biological studies. Cancer Biother. Radiopharm. 11: 303-308.
42. Yoshida H., H. Enomoto, M. Tagawa, K. Takenaga, K. Tasaki, K. Nakagawara, N. Ohnuma, H. Takahashi, and S. Skiyama. Impaired tumorgenicity and decreased liver metastasis of murine neuroblastoma cells engineered to secrete interleukin-2 or granulocyte macrophage colony-stimulating factor. 1998. Cancer Gene Ther. 5: 67-73.
43. Shimizu, T., A. Berhanu, R. E. Redkinger, Jr., W. Simon, M. T. Lotze, and E. M. Barksdale, Jr. 2001. Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. J. Pediatr. Surg. 36: 1285-1292.
44. Redlinger, R. E., Jr., B. Mailliard, and E. M. Barksdale, Jr. 2003. Neuroblastoma and dendritic cell function. Semin. Pediatr. Surg. 13: 61-71.